GlaxoSmithKline (LON:GSK) Given New GBX 1,540 Price Target at Kepler Capital Markets

GlaxoSmithKline (LON:GSK) had its price objective hoisted by research analysts at Kepler Capital Markets from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) in a research note issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “hold” rating on the stock. Kepler Capital Markets’ price target would suggest a potential downside of 2.73% from the stock’s previous close.

A number of other equities analysts have also issued reports on GSK. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research note on Tuesday, April 9th. Deutsche Bank set a GBX 1,520 ($19.86) price target on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday, February 12th. UBS Group lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating and decreased their price target for the company from GBX 1,700 ($22.21) to GBX 1,650 ($21.56) in a research note on Friday, February 22nd. Barclays reaffirmed an “equal weight” rating on shares of GlaxoSmithKline in a research note on Monday, March 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,750 ($22.87) price target on shares of GlaxoSmithKline in a research note on Tuesday, April 23rd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of GBX 1,531.41 ($20.01).

GSK stock traded up GBX 9.40 ($0.12) on Tuesday, reaching GBX 1,583.20 ($20.69). The company’s stock had a trading volume of 5,226,834 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 52 week low of GBX 1,408.80 ($18.41) and a 52 week high of GBX 1,648.80 ($21.54). The firm has a market capitalization of $78.32 billion and a price-to-earnings ratio of 20.17. The company has a debt-to-equity ratio of 942.07, a current ratio of 0.72 and a quick ratio of 0.45.

In related news, insider Manvinder Singh Banga acquired 458 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was bought at an average price of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Insiders have bought a total of 474 shares of company stock valued at $742,847 in the last quarter.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Article: Capital gains and your 401(k) or IRA

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.